FDA Places Partial Hold on Cervical Cancer Trial of AIM2CERV

January 24, 2019 – The FDA has placed a partial clinical hold on the phase III AIM2CERV trial (NCT02853604) evaluating the use of axalimogene filolisbac in patients with high-risk locally advanced cervical cancer, according to Advaxis, Inc., the developer of the investigational immunotherapy agent. The communication from the FDA cites that the partial hold has been put in place until additional information on chemistry, manufacturing, and control … (leggi tutto)